Search
Dexamethasone
go.drugbank.com/drugs/DB01234ApprovedInvestigationalVet approvedDexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318]
Leucovorin
go.drugbank.com/drugs/DB00650ApprovedInvestigational[L56092, A257419] Unlike folic acid, leucovorin does not require the enzyme dihydrofolate reductase (DHFR) for activation, allowing it to function even when DHFR is inhibited by drugs like methotrexate
Valbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigational[A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. … This approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial.
YSIL6
go.drugbank.com/drugs/DB05017ExperimentalThe molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.
Apraclonidine
go.drugbank.com/drugs/DB00964ApprovedInvestigationalApraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist.
Methylphenidate
go.drugbank.com/drugs/DB00422ApprovedInvestigational[A631] OROS is comprised of an osmotically active trilayer core surrounded by a semipermeable membrane with an immediate-release drug overcoat. … [A177541, A177544] Methylphenidate's beneficial effects in sustaining attention have also been shown to be mediated by alpha-1 adrenergic receptor activity.
Raxibacumab
go.drugbank.com/drugs/DB08902ApprovedInvestigationalRaxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.
Urokinase
go.drugbank.com/drugs/DB00013ApprovedInvestigationalWithdrawn[A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943] Urokinase was granted FDA approval on 16 January 1978.[L12138]
Dofetilide
go.drugbank.com/drugs/DB00204ApprovedInvestigationalDofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation